Top

Published in:

Open Access 01-05-2017 | Psychiatry and Preclinical Psychiatric Studies - Original Article

Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects

Authors: Helga Höifödt Lidö, Susanne Jonsson, Petri Hyytiä, Mia Ericson, Bo Söderpalm

Published in: Journal of Neural Transmission | Issue 5/2017

Abstract

The glycine transporter-1 inhibitor Org25935 is a promising candidate in a treatment concept for alcohol use disorder targeting the glycine system. Org25935 inhibits ethanol-induced dopamine elevation in brain reward regions and reduces ethanol intake in Wistar rats. This study aimed to further characterise the compound and used ethanol consumption, behavioral measures, and gene expression as parameters to investigate the effects in Wistar rats and, as pharmacogenetic comparison, Alko-Alcohol (AA) rats. Animals were provided limited access to ethanol in a two-bottle free-choice paradigm with daily drug administration. Acute effects of Org25935 were estimated using locomotor activity and neurobehavioral status. Effects on gene expression in Wistar rats were measured with qPCR. The higher but not the lower dose of Org25935 reduced alcohol intake in Wistar rats. Unexpectedly, Org25935 reduced both ethanol and water intake and induced strong CNS-depressive effects in AA-rats (withdrawn from further studies). Neurobehavioral effects by Org25935 differed between the strains (AA-rats towards sedation). Org25935 did not affect gene expression at the mRNA level in the glycine system of Wistar rats. The data indicate a small therapeutic range for the anti-alcohol properties of Org25935, a finding that may guide further evaluations of the clinical utility of GlyT-1 inhibitors. The results point to the importance of pharmacogenetic considerations when developing drugs for alcohol-related medical concerns. Despite the lack of successful clinical outcomes, to date, the heterogeneity of drug action of Org25935 and similar agents and the unmet medical need justify further studies of glycinergic compounds in alcohol use disorder.

Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, Pinard E, Knoflach F, Schlotterbeck G, Hainzl D, Wettstein JG (2012) Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62:1152–1161CrossRefPubMed

Andrews N, Ge J, Walker G (2007) Effect of the selective reuptake (GlyT-1) inhibitor Org25935 on glycine levels in CSF and dialysates. Eur Neuropsychopharmacol 17(Suppl 4):s497–s498

Betz H, Gomeza J, Armsen W, Scholze P, Eulenburg V (2006) Glycine transporters: essential regulators of synaptic transmission. Biochem Soc Trans 34:55–58CrossRefPubMed

Bowery NG, Smart TG (2006) GABA and glycine as neurotransmitters: a brief history. Br J Pharmacol 147(Suppl 1):S109–S119PubMedPubMedCentral

Castner SA, Murthy NV, Ridler K, Herdon H, Roberts BM, Weinzimmer DP, Huang Y, Zheng MQ, Rabiner EA, Gunn RN, Carson RE, Williams GV, Laruelle M (2014) Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates. Neuropsychopharmacology 39(12):2742–2749CrossRefPubMedPubMedCentral

Cubelos B, Gimenez C, Zafra F (2005) Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15:448–459CrossRefPubMed

De Bejczy A, Nations KR, Szegedi A, Schoemaker J, Ruwe F, Soderpalm B (2014) Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 38:2427–2435CrossRefPubMed

Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278CrossRefPubMedPubMedCentral

Eddins D, Hamill TG, Puri V, Cannon CE, Vivian JA, Sanabria-Bohorquez SM, Cook JJ, Morrow JA, Thomson F, Uslaner JM (2014) The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology 231:511–519CrossRefPubMed

Egli M (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 10:309–319CrossRefPubMed

Eriksson K (1968) Genetic selection for voluntary alcohol consumption in albino rat. Science 159:739–741CrossRefPubMed

Fahlke C, Hansen S, Engel JA, Hard E (1994) Effects of ventral striatal 6-OHDA lesions or amphetamine sensitization on ethanol consumption in the rat. Pharmacol Biochem Behav 47:345–349CrossRefPubMed

Ge J, Hamilton M, Shahid D, Hill R, Walker G (2001) The effects of Org25935 on the extracellular levels of glycine in brain regions of freely moving rats using microdialysis. Br J Pharmacol 133(Proc Suppl):135

Gomeza J, Ohno K, Betz H (2003) Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr Opin Drug Discov Devel 6:675–682PubMed

Grudzinska J, Schemm R, Haeger S, Nicke A, Schmalzing G, Betz H, Laube B (2005) The beta subunit determines the ligand binding properties of synaptic glycine receptors. Neuron 45:727–739CrossRefPubMed

Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811–825CrossRefPubMed

Harsing LG Jr, Juranyi Z, Gacsalyi I, Tapolcsanyi P, Czompa A, Matyus P (2006) Glycine transporter type-1 and its inhibitors. Curr Med Chem 13:1017–1044CrossRefPubMed

Harvey RJ, Yee BK (2013) Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 12:866–885CrossRefPubMed

Hashimoto K (2011) Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr Pharm Des 17:112–120CrossRefPubMed

Heffner TG, Hartman JA, Seiden LS (1980) A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13:453–456CrossRefPubMed

Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855–876CrossRefPubMed

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36CrossRefPubMed

Hyytia P (1993) Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav 45:697–701CrossRefPubMed

Hyytia P, Ingman K, Soini SL, Laitinen JT, Korpi ER (1999) Effects of continuous opioid receptor blockade on alcohol intake and up-regulation of opioid receptor subtype signalling in a genetic model of high alcohol drinking. Naunyn Schmiedebergs Arch Pharmacol 360:391–401CrossRefPubMed

Ingman K, Sallinen J, Honkanen A, Korpi ER (2004) Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats. Pharmacol Biochem Behav 77:847–854CrossRefPubMed

Jonsson S, Kerekes N, Hyytia P, Ericson M, Soderpalm B (2009) Glycine receptor expression in the forebrain of male AA/ANA rats. Brain Res 1305(Suppl):S27–S36CrossRefPubMed

Jonsson S, Morud J, Pickering C, Adermark L, Ericson M, Soderpalm B (2012) Changes in glycine receptor subunit expression in forebrain regions of the Wistar rat over development. Brain Res 1446:12–21CrossRefPubMed

Kirsch J (2006) Glycinergic transmission. Cell Tissue Res 326:535–540CrossRefPubMed

Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science 242:715–723CrossRefPubMed

Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238CrossRefPubMed

Kopec K, Flood DG, Gasior M, Mckenna BA, Zuvich E, Schreiber J, Salvino JM, Durkin JT, Ator MA, Marino MJ (2010) Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem Pharmacol 80:1407–1417CrossRefPubMed

Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, Gelernter J, Lappalainen J (2006) Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry 63:957–968CrossRefPubMed

Lidö HH, Stomberg R, Fagerberg A, Ericson M, Soderpalm B (2009) The glycine reuptake inhibitor org 25935 interacts with basal and ethanol-induced dopamine release in rat nucleus accumbens. Alcohol Clin Exp Res 33:1151–1157CrossRefPubMed

Lidö HH, Ericson M, Marston H, Söderpalm B (2011) A role for accumbal glycine receptors in modulation of dopamine release by the glycine transporter-1 inhibitor org25935. Front Psychiatry 2:8CrossRefPubMedPubMedCentral

Lifö HH, Marston H, Ericson M, Söderpalm B (2011) The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addict Biol 7(5):897–907

Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, De Kam ML, Franson KL, Cohen AF, Van Gerven JM (2013) Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men. Br J Clin Pharmacol 75:1455–1467CrossRefPubMed

Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F et al (2013) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224–2260CrossRef

Mattson JL, Spencer PJ, Albee RR (1996) A performance standard for clinical and functional observational battery examinations of rats. J Am Coll Toxicol 15(3):239–254CrossRef

Molander A, Söderpalm B (2005a) Accumbal strychnine-sensitive glycine receptors: an access point for ethanol to the brain reward system. Alcohol Clin Exp Res 29:27–37CrossRefPubMed

Molander A, Söderpalm B (2005b) Glycine receptors regulate dopamine release in the rat nucleus accumbens. Alcohol Clin Exp Res 29:17–26CrossRefPubMed

Molander A, Löf E, Stomberg R, Ericson M, Söderpalm B (2005) Involvement of accumbal glycine receptors in the regulation of voluntary ethanol intake in the rat. Alcohol Clin Exp Res 29:38–45CrossRefPubMed

Molander A, Lido HH, Lof E, Ericson M, Soderpalm B (2007) The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats. Alcohol Alcohol 42:11–18CrossRefPubMed

Ojanen SP, Hyytia P, Kiianmaa K (2006) Enhanced morphine-induced ethanol drinking in alcohol-preferring alko alcohol rats sensitized to morphine. Alcohol Clin Exp Res 30:621–629CrossRefPubMed

Olive MF (2002) Interactions between taurine and ethanol in the central nervous system. Amino Acids 23:345–357CrossRefPubMed

Olsen RW, Hanchar HJ, Meera P, Wallner M (2007) GABAA receptor subtypes: the “one glass of wine” receptors. Alcohol 41:201–209CrossRefPubMedPubMedCentral

Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, Katner J, Gordon KD, Wade MR, Man T, Nomikos GG, Phebus LA, Cauvin AJ, Johnson KW, Jones CK, Hoffmann BJ, Sandusky GE, Walter MW, Porter WJ, Yang L, Merchant KM, Shannon HE, Svensson KA (2008) Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55:743–754CrossRefPubMed

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45CrossRefPubMedPubMedCentral

Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M, Cottone P, Madamba SG, Stouffer DG, Zorrilla EP, Koob GF, Siggins GR, Parsons LH (2010) Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence. Biol Psychiatry 67:831–839CrossRefPubMedPubMedCentral

Roberto M, Gilpin NW, Siggins GR (2012) The central amygdala and alcohol: role of gamma-aminobutyric acid, glutamate, and neuropeptides. Cold Spring Harb Perspect Med 2:a012195CrossRefPubMedPubMedCentral

Soderpalm B, Ericson M (2013) Neurocircuitry Involved in the development of alcohol addiction: the dopamine system and its access points. Curr Top Behav Neurosci 13:127–161CrossRefPubMed

Soderpalm AH, Hansen S (1998) Benzodiazepines enhance the consumption and palatability of alcohol in the rat. Psychopharmacology 137:215–222CrossRefPubMed

Soderpalm B, Lof E, Ericson M (2009) Mechanistic studies of ethanol’s interaction with the mesolimbic dopamine reward system. Pharmacopsychiatry 42(Suppl 1):S87–S94CrossRefPubMed

Sommer W, Hyytia P, Kiianmaa K (2006) The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. Addict Biol 11:289–309CrossRefPubMed

Spanagel R (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89:649–705CrossRefPubMed

Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29:109–115CrossRefPubMed

Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71:637–646CrossRefPubMed

Vengeliene V, Leonardi-Essmann F, Sommer WH, Marston HM, Spanagel R (2010) Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. Biol Psychiatry 68:704–711CrossRefPubMed

Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007) Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64:1575–1579CrossRefPubMed

Walther L, De Bejczy A, Lof E, Hansson T, Andersson A, Guterstam J, Hammarberg A, Asanovska G, Franck J, Soderpalm B, Isaksson A (2015) Phosphatidylethanol is superior to carbohydrate-deficient transferrin and gamma-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level. Alcohol Clin Exp Res 39:2200–2208CrossRefPubMed

Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6:243–251CrossRefPubMed

Yevenes GE, Moraga-Cid G, Peoples RW, Schmalzing G, Aguayo LG (2008) A selective G betagamma-linked intracellular mechanism for modulation of a ligand-gated ion channel by ethanol. Proc Natl Acad Sci USA 105:20523–20528CrossRefPubMedPubMedCentral

Zafra F, Gimenez C (2008) Glycine transporters and synaptic function. IUBMB Life 60:810–817CrossRefPubMed

Title: Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects
Authors: Helga Höifödt Lidö
Susanne Jonsson
Petri Hyytiä
Mia Ericson
Bo Söderpalm
Publication date: 01-05-2017
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 5/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-017-1685-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Child regulative temperament as a mediator of parenting in the development of depressive symptoms: a longitudinal study from early childhood to preadolescence

Association between cognitive impairment and urinary dysfunction in Parkinson’s disease

Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)

The missing link between sleep disorders and age-related dementia: recent evidence and plausible mechanisms

Diagnostic classification of unipolar depression based on resting-state functional connectivity MRI: effects of generalization to a diverse sample

Differential diagnosis between patients with probable Alzheimer’s disease, Parkinson’s disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features